We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » BMS BEGINS CORRECTING MISLEADING PRAVACHOL ADS
BMS BEGINS CORRECTING MISLEADING PRAVACHOL ADS
February 23, 2004
Bristol-Myers Squibb (BMS) has started running corrective ads for its leading cholesterol drug following FDA allegations last summer that the firm ran misleading direct-to-consumer (DTC) ads.